# EDGAR Filing Document

**Accession Number:** 0001997403
**File Stem:** 0001376474-26-000264
**Filing Date:** 2026-4
**Character Count:** 20059
**Document Hash:** 149bed43986d5a62f3f02afb7637e8f5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001376474-26-000264.hdr.sgml**: 20260402

**ACCESSION NUMBER**: 0001376474-26-000264

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260402

**DATE AS OF CHANGE**: 20260402

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ZenaTech, Inc.
- **CENTRAL INDEX KEY:** 0001997403
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-PREPACKAGED SOFTWARE [7372]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 000000000
- **STATE OF INCORPORATION:** Z4
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94804
- **FILM NUMBER:** 26831640

**BUSINESS ADDRESS:**
- **STREET 1:** 777 HORNBY STREET, SUITE 600
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6Z 1S4
- **BUSINESS PHONE:** 647-249-1622

**MAIL ADDRESS:**
- **STREET 1:** 777 HORNBY STREET, SUITE 600
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6Z 1S4
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Passley Shaun
- **CENTRAL INDEX KEY:** 0001671957

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** 201 W. LAKE ST. 135
- **CITY:** CH
- **STATE:** IL
- **ZIP:** 60606

## Ex-99

**EXHIBIT A**

**JOINT FILING AGREEMENT**

In accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to jointly prepare and file a Schedule 13D (including any future amendments thereto) reporting each of the undersigned's ownership of securities of ZenaTech, Inc. and further agree to the filing of this Agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to file on its behalf any and all amendment to such Schedule 13D. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

Date: April 1, 2026 Epazz, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Per: _<u>/s/ Dr. Shaun Passley_</u>__<br> Name: Dr. Shaun Passley<br> Title: Director

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_<u>/s/</u> <u>Dr. Shaun Passley</u>________<br> Dr. Shaun Passley

## Ex-99

**EXHIBIT B**

**SHARE OWNERSHIP REPORT**

The following table sets forth information relating to the shares issued pursuant to the approvals obtained at the Special Meeting:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; **Name**  | &nbsp;&nbsp; **Type of Security Issued<sup>(1)</sup>** | &nbsp;&nbsp; **Number of Shares Issued<sup>(2)</sup>** |
| &nbsp;&nbsp; Dr. Shaun Passley | &nbsp;&nbsp; Super-Voting Shares<br> Preferred Shares | &nbsp;&nbsp; 25000<br> 1500000 |
| &nbsp;&nbsp; Epazz, Inc. | &nbsp;&nbsp; Super-Voting Shares<br> Preferred Shares | &nbsp;&nbsp; 100000<br> 10000000 |

---

(1) Each super-voting share carries 1,000 votes per share. The preferred shares are non-voting and may be converted to common shares on the basis of three common shares for each preferred share converted.

(2) Each person named in the table has the sole power to vote the shares owned by the person. In addition, Dr. Passley is the sole director and officer of Epazz, and is its principal shareholder with 95% voting control of Epazz, and, accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz.

The following table sets forth information relating to shares of the Company held by Dr. Passley, Epazz and Ameritek currently:<br>

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp; **Name** | &nbsp;&nbsp; **Type of Ownership** | &nbsp;&nbsp; **Type of Security Owned** | &nbsp;&nbsp; **Number of Shares Owned** | &nbsp;&nbsp; **Percentage of Shares Outstanding <sup>(1)</sup>** |
| &nbsp;&nbsp; Dr. Shaun Passley | &nbsp;&nbsp; Beneficial and of Record | &nbsp;&nbsp; Common Shares<br> Super Voting Shares<br> Preferred Shares | &nbsp;&nbsp; 7668205<br> 35000<br> 5120000 | &nbsp;&nbsp; 12.4%<br> 18.9%<br> 12.5% |
| &nbsp;&nbsp; Epazz, Inc. <sup>(2)</sup> | &nbsp;&nbsp; Beneficial and of Record | &nbsp;&nbsp; Common Shares<br> Super Voting Shares<br> Preferred Shares | &nbsp;&nbsp; 10867301<br> 145000<br> 21700000 | &nbsp;&nbsp; 17.7%<br> 78.4%<br> 75.3% |
| &nbsp;&nbsp; Ameritek Ventures, Inc. <sup>(3)(4)</sup> | &nbsp;&nbsp; Beneficial and of Record | &nbsp;&nbsp; Common Shares<br> Super Voting Shares<br> Preferred Shares | &nbsp;&nbsp; 1583333<br> 5000<br> 750000 | &nbsp;&nbsp; 2.5%<br> 2.7%<br> 2.6% |
| &nbsp;&nbsp; Directors and Officers (other than Dr. Passley) | &nbsp;&nbsp; Beneficial and of Record | &nbsp;&nbsp; Common Shares<br> Super Voting Shares<br> Preferred Shares | &nbsp;&nbsp; 644784<br> -<br> - | &nbsp;&nbsp; 1.0%<br> -<br> - |

---

(1) Based on 61,389,794 common shares, 185,000 super-voting shares and 28,770,000 preferred sharesissued and outstanding.

(2) Dr. Shaun Passley is the sole director and officer of Epazz and is its principal shareholder with 95% voting control of Epazz.

(3) Dr. Shaun Passley is the sole director and officer of Ameritek.

(4) Epazz is the principal shareholder with 95% voting control of Ameritek.

(5) Each person named in the table has the sole power to vote the shares owned by the person. In addition, Dr. Passley is the sole director and officer of Epazz, and is its principal shareholder with 95% voting control of Epazz.; Dr. Passley is a director, officer, and principal shareholder of Ameritek of which Epazz, is the principal shareholder with 95% voting control of Ameritek.; and accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz and Ameritek.

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**ZenaTech, Inc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**—**

*(CUSIP Number)*

**Dr. Shaun Passley**<br>777 Hornby Street, Suite 1460<br>Vancouver A1 V6Z 1S4<br>(647) 249-1622

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/17/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dr. Shaun Passley** | Name of reporting person<br>**Dr. Shaun Passley** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**58028205.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**287828839.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**58028205.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**287828839.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**287828839.00** | Aggregate amount beneficially owned by each reporting person<br>**287828839.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**86.5%** | Percent of class represented by amount in Row (11)<br>**86.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Comprised of (i) 7,668,205 common shares, 5,120,000 preferred shares and 35,000 super-voting shares held by Dr. Passley, (ii) 10,867,301 common shares, 21,700,000 preferred shares and 145,000 super-voting shares held by Epazz, Inc. ("Epazz"), and (iii) 1,583,333 common shares, 750,000 preferred shares and 5,000 super-voting shares held by Ameritek Ventures Inc. ("Ameritek"). Each preferred share is convertible into three common shares. Each super-voting share carries 1,000 votes per share. The aggregate number of votes available at the Company, assuming the conversion of all preferred shares to common shares and the exercise of voting rights attached to such common shares and the exercise of voting rights attached to all super-voting shares, is 332,699,794.

Dr. Passley is the sole director and officer of Epazz and is its principal shareholder with 95% voting control of Epazz, Inc. Dr. Passley is a director, officer, and principal shareholder of Ameritek of which Epazz is the principal shareholder with 95% voting control of Ameritek. Accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz and Ameritek.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Epazz Inc** | Name of reporting person<br>**Epazz Inc** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**WYOMING** | Citizenship or place of organization<br>**WYOMING** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**220967301.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**220967301.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**220967301.00** | Aggregate amount beneficially owned by each reporting person<br>**220967301.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**66.4%** | Percent of class represented by amount in Row (11)<br>**66.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Comprised of 10,867,301 common shares, 21,700,000 preferred shares and 145,000 super-voting shares held by Epazz. Each preferred share is convertible into three common shares. Each super-voting share carries 1,000 votes per share. The aggregate number of votes available at the Company, assuming the conversion of all preferred shares to common shares and the exercise of voting rights attached to such common shares and the exercise of voting rights attached to all super-voting shares, is 332,699,794.

Dr. Passley is the sole director and officer of Epazz and is its principal shareholder with 95% voting control of Epazz, Inc. Dr. Passley is a director, officer, and principal shareholder of Ameritek of which Epazz is the principal shareholder with 95% voting control of Ameritek. Accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz and Ameritek.

| **CUSIP No.** | **—** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ameritek Ventures, Inc.** | Name of reporting person<br>**Ameritek Ventures, Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**NEVADA** | Citizenship or place of organization<br>**NEVADA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**8333333.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**8333333.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**8333333.00** | Aggregate amount beneficially owned by each reporting person<br>**8333333.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**2.5%** | Percent of class represented by amount in Row (11)<br>**2.5%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Comprised of 1,583,333 common shares, 750,000 preferred shares and 5,000 super-voting shares held by Ameritek.  Each preferred share is convertible into three common shares. Each super-voting share carries 1,000 votes per share. The aggregate number of votes available at the Company, assuming the conversion of all preferred shares to common shares and the exercise of voting rights attached to such common shares and the exercise of voting rights attached to all super-voting shares, is 332,699,794.

Dr. Passley is the sole director and officer of Epazz and is its principal shareholder with 95% voting control of Epazz, Inc. Dr. Passley is a director, officer, and principal shareholder of Ameritek of which Epazz is the principal shareholder with 95% voting control of Ameritek. Accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz and Ameritek.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
ZenaTech, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
777 HORNBY STREET, SUITE 1460, VANCOUVER, A1, V6Z 1S4

This Schedule 13D relates to the common shares, preferred shares and super-voting shares of ZenaTech Inc., a British Columbia, Canada corporation (the "Issuer"). The principal executive offices of the Issuer are located at Suite 1460, 777 Hornby Street, Vancouver, British Columbia V6Z 1S4 Canada.

**Item 4. Purpose of Transaction**

The Reporting Persons acquired the Issuer's common stock for investment purposes.  None of the Reporting Persons have any plans or proposals which relate to or would result in any of the matters listed in Items 4(a) to 4(j) of Schedule 13D.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The beneficial holdings of Epazz, Ameritek and Dr. Passley in the Company are set forth in Exhibit B hereto.

**(b)**
Dr. Passley is the sole director and officer of Epazz, and is its principal shareholder with 95% voting control of Epazz. Dr. Passley is a director, officer, and principal shareholder of Ameritek of which Epazz is the principal shareholder with 95% voting control of Ameritek. Accordingly, Dr. Passley controls the voting rights attached to the shares of the Issuer owned by Epazz and Ameritek.

**(c)**
As described in the Information Circular, at the Company's Special Meeting held January 30, 2026, the shareholders of the Company approved (i) the issuance of equity grants to Dr. Passley pursuant to the New CEO Agreement and (ii) the acquisition by the Company of certain assets from Epazz. In consideration for the assets acquired, the Company issued super-voting shares and preferred shares to Dr. Passley and Epazz. See Exhibit B hereto.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

None.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dr. Shaun Passley

**Signature:** Shaun Passley

**Name/Title:** Individual

**Date:** 04/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Epazz Inc

**Signature:** Shaun Passley

**Name/Title:** Director

**Date:** 04/02/2026

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ameritek Ventures, Inc.

**Signature:** Shaun Passley

**Name/Title:** Director

**Date:** 04/02/2026